According to a panel of experts who presented at a briefing this week in the Senate Dirksen Office Building on Capitol Hill, new legislation is needed to improve the quality of treatment options available to premature newborns. While scores of new treatment options have become available for the pediatric patient population as a whole—thanks in large part to incentives implemented over the past two decades – panelists noted that only one drug has been approved specifically for use in neonates – infants in the first 28 days of life, who often face rare conditions that don’t exist in the adult population or even older infants.
